N/A N=129 JETi Lower Extremity Arterial Thrombosis
Arterial Thrombosis
Primary: Primary Effectiveness Endpoint - Clot Removal Grade From Pre-JETi to Post-JETi - Core Lab Assessed - Per Vessel Analysis — 36; 41; 52; 93 Vessels
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=411 Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Deep Vein Thrombosis of Lower Limb · Pulmonary Embolism (PE) · Bleeding
Primary: Events of Deep Vein Thrombosis (DVT) — 8; 8; 5; 6 Events — p=>0.05
Phase 2 N=203 Edoxaban in Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Percentage of Participants With Clinically Relevant Bleeding During Treatment — 8; 11; 6; 6 percentage of participants
Phase 4 N=208 Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Phase 3 N=11,016 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Phase 3 N=14 Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants
N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Phase 4 N=60 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
Phase 3 N=6,564 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Phase 3 N=1,343 Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Venous Thromboembolism
Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001
Phase 3 N=5,395 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
Phase 3 N=2,856 Secondary Prevention of Venous Thrombo Embolism (VTE).
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137
Phase 4 N=131 Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
N/A N=1,000 FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Subjects With Major Adverse Events — 24; 964 Participants
N/A N=1,480 An International Pulmonary Embolism Registry Using EKOS
Pulmonary Embolism and Thrombosis
Primary: Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) — -22.6; -22.6 Percent change
Phase 4 N=49 Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
Primary Total Hip and Knee Arthroplasty
Primary: Blood Loss — 6; 1 participants
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
Phase 1 N=8 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
Pulmonary Embolism · Deep Vein Thrombosis · Venous Thromboembolism
Primary: Safety — 0 participants
Phase 4 N=60 Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Ischemic Stroke
Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Phase 3 N=2,013 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
Venous Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 61; 69 Participants — p=< 0.0001
Phase 3 N=6,528 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
Venous Thrombosis · Pulmonary Embolism
Primary: Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population — 2.71…
N/A N=115 Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)
Stroke
Primary: Neurological Condition of the Patient — 23; 52; 60; 29 patients
Phase 4 N=100 Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
Atrial Fibrillation · Device Related Thrombus · Left Atrial Appendage Thrombosis
Primary: Device Related Thrombus (DRT) at 90 Days — 1 Participants